

1 **Supporting Information**

2 **Microneedle Patches Loaded with Nanovesicles for Glucose Transporter-**  
3 **mediated Insulin Delivery**

4  
5 *Qian Chen<sup>1, 2, 3, 9 †\*</sup>, Zhisheng Xiao<sup>9 †</sup>, Chao Wang<sup>3,9 †</sup>, Guojun Chen<sup>1, 2, 3</sup>, Yuqi Zhang<sup>1, 2, 3, 4</sup>,*  
6 *Xudong Zhang<sup>1, 2, 3</sup>, Xiao Han<sup>1, 2</sup>, Jinqiang Wang<sup>1, 2, 3, 4</sup>, Xiao Ye<sup>10,11 \*</sup> Mark R Prausnitz<sup>12</sup>, Song*  
7 *Li<sup>1, 2</sup> and Zhen Gu<sup>1-8\*</sup>*

8  
9 1 Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA  
10 90095, USA.

11 2 California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA  
12 90095, USA.

13 3 Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill  
14 and North Carolina State University, Raleigh, NC 27695, USA.

15 4 Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, College of  
16 Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.

17 5 Jinhua Institute of Zhejiang University, Jinhua 321299, China;

18 6 Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang  
19 University, Hangzhou 310016, China;

20 7 Zhejiang Laboratory of Systems & Precision Medicine, Zhejiang University Medical Center,  
21 Hangzhou 311121, China;

22 8 MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of  
23 Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, China.

24 9 Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for  
25 Carbon-Based Functional Materials & Devices, Soochow University, Suzhou 215123, China

26 10 Geriatric Medicine Center, Department of Endocrinology, Zhejiang Provincial People's  
27 Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang,  
28 China 310014.

29 11 Key Laboratory for Diagnosis and Treatment of Endocrine Gland Diseases of Zhejiang

1 Province, Hangzhou, Zhejiang 310014, China.

2 12 School of Chemical and Biomolecular Engineering, Georgia Institute of Technology,  
3 Atlanta, GA 30332, USA.

4 \* Corresponding author: E-mail: guzhen@ucla.edu, chenqian@suda.edu.cn,  
5 semper\_fi@foxmail.com

6

## 7 **Methods**

8 **Synthesis of Glu-Insulin.** Glu-Insulin conjugate was synthesized in a two-step process. In brief,  
9 insulin was thiolated by reacting with Traut's Reagent (2-iminothiolane, Pierce) in PBS  
10 (pH=8.0) at a molar ratio of 1:5 for 2 h at 4 °C. Thereafter, excess Traut's reagent was removed  
11 using a centrifugal filter device (molecular weight cutoff MWCO =3 kDa) to purify the SH-  
12 insulin. D-(+)-Glucosamine was mixed with sulfosuccinimidyl-4-(*N*-maleimidomethyl)-  
13 cyclohexane-1-carboxylate (Sulfo-SMCC, Pierce) in PBS (pH=7.4) at a molar ratio of 1:1 for  
14 2 h at room temperature. Finally, SMCC-activated glucosamine and insulin-SH were mixed in  
15 PBS (pH=8.0) at a molar ratio of insulin: glucosamine=1:10. After a 24 h reaction at 4 °C, the  
16 excess glucosamine was removed using a centrifugal filter device (MWCO =3 kDa). The  
17 obtained Glu-Insulin was stored at 4 °C until use.

18

19 **GLUT1 expression and purification.** The gene encoding GLUT1 from rat was amplified from  
20 the plasmid prGT3 (Addgene 15993)<sup>1</sup> and subcloned into the pET-28a vector (Novagen) with  
21 primers rGLUT1-s (5'-GCAAATGGGTCGCGGATCCATGGAGCCCAGCAGC-3', BamHI  
22 underlined) and rGLUT-a (5'-CGAGTGCGGCCGCAAGCTTTCACACTTGGGAGTCAG-  
23 3', Hind III underlined). The obtained pET28a-rGLUT1 was transformed into *Escherichia coli*  
24 Rosetta (DE3) pLysS cells for rGLUT1 expression. Briefly, a fresh *E. coli* colony was  
25 inoculated into 5 mL of LB medium (supplemented with 10 µg/mL kanamycin and 34 µg/mL  
26 chloromycetin) at 37 °C overnight. The cell culture was then diluted 100-fold with fresh LB  
27 medium and cultured for another 2-3 h (OD<sub>600</sub> 0.6-0.8). Afterward, 0.5 mM isopropyl β-D-1-  
28 thiogalactopyranoside (IPTG) was added to induce rGLUT1 expression at 20 °C for 8 h. The  
29 cells were collected by centrifugation at 4000 ×g for 15 min and resuspended in Buffer A (20  
30 mM Tris-HCl pH 8.0, 0.15 M NaCl, 10 mM imidazole, 5% glycerol, 1 mM PMSF, 0.5 mg/mL

1 lysozyme, 0.4 mg/mL DNase I, and 2% DDM). The suspension was incubated at room  
2 temperature for 30 min on ice for another 30 min. The cells were then lysed by sonication, and  
3 cell debris was removed by centrifugation (20000×g, 10 min). The clear lysate was added to a  
4 column containing 1 mL Ni-NTA resin (Qiagen). After washing the column with Buffer B (20  
5 mM Tris-HCl pH 8.0, 0.15 M NaCl, 25 mM imidazole, 5% glycerol, and 0.05% DDM),  
6 rGLUT1 was eluted with Buffer C (20 mM Tris-HCl pH 8.0, 0.15 M NaCl and 500 mM  
7 imidazole, 5% glycerol and 0.05% DDM). The purified rGLUT1 was quantified by the  
8 Bradford assay (Bio–Rad) and analyzed by SDS–PAGE.

9  
10 **Mechanical strength test.** The mechanical strength of MNs was measured by pressing MNs  
11 against a stainless steel plate. The initial gauge was set as 2.00 mm between the MN tips and  
12 the stainless steel plate, with 10.00 N as the load cell capacity. The speed of the top stainless  
13 steel plate movement toward the MNs was 0.1 mm/s. The failure force of MNs was recorded  
14 as the needle began to buckle.

15  
16 ***In vitro* skin penetration test.** To evaluate the *in vitro* skin penetrating ability of MNs, the  
17 MNs were inserted into the skin of mice for 10 min. The skin was stained with trypan blue for  
18 10 min before imaging by optical microscopy (Leica EZ4 D stereomicroscope).

19  
20 **Intraperitoneal glucose tolerance tests (IPGTTs).** A glucose tolerance test was conducted to  
21 confirm the *in vivo* glucose responsiveness of MNs 1 h post-administration of RBC-insulin-  
22 MN or liposome(GLUT1)-insulin-MN and free insulin. Briefly, mice were fasted overnight  
23 and administrated with RBC-insulin-MN or liposome(GLUT1)-insulin-MN and free insulin,  
24 and then a glucose solution in PBS was intraperitoneally injected into all mice at a dose of 1.5  
25 g/kg. The glucose levels were monitored over time after injection. The glucose tolerance test  
26 on healthy mice was used as the control.


## 27 28 **Reference**

29 1. Birnbaum, M. J.; Haspel, H. C.; Rosen, O. M., Cloning and characterization of a cDNA  
30 encoding the rat brain glucose-transporter protein. *Proc. Natl. Acad. Sci.* **1986**, 83 (16), 5784-

1 5788.


2

3




1  
2  
3  
4  
5  
6

**Supplementary Figure 1.** Immunofluorescence imaging of GLUT4 in RBC vesicles indicated that GLUT4 was reserved in RBC vesicles (scale bar = 10  $\mu\text{m}$ ).



7  
8  
9  
10


**Supplementary Figure 2.** Matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS) assay of glucose-insulin conjugates. The molecular weight of Glc-Insulin conjugates was  $\sim 6377$ .



1

2 **Supplementary Figure 3.** Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE)  
3 analysis of purified GLUT1.

4



5

6 **Supplementary Figure 4.** Confocal microscopy images of Glu-Insulin-attached liposome-GLUT1  
7 untreated or treated with 400 mg/dL glucose solution (scale bar = 10  $\mu\text{m}$ ).

8

9

10